Related Experiment Video
Updated: Aug 9, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Fluvastatin in combination with other lipid-lowering agents
1Cardiovascular Clinical Research, Sandoz Research Institute, East Hanover, NJ 07936, USA.
British Journal of Clinical Practice. Supplement
|January 1, 1996
Summary
Fluvastatin combined with bezafibrate or cholestyramine effectively lowers LDL cholesterol. Combination therapy with fluvastatin and niacin also showed significant LDL reduction without myopathy, suggesting optimal management for hypercholesterolemia.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism Disorders
- Pharmacotherapy
Background:
- HMGCoA reductase inhibitors, like fluvastatin, are key in managing hypercholesterolemia.
- Combination therapy is explored to enhance lipid-lowering efficacy.
- Safety of combining fluvastatin with other lipid-modifying agents requires investigation.
Purpose of the Study:
- To evaluate fluvastatin in combination with bezafibrate, cholestyramine, and niacin.
- To assess the efficacy and safety of these combination therapies.
- To determine optimal treatment strategies for hypercholesterolemia and mixed dyslipidemia.
Main Methods:
- Double-blind trial of fluvastatin with bezafibrate or cholestyramine in familial hypercholesterolemia.
- Low-dose fluvastatin and cholestyramine combinations were studied.
- Sequential administration of fluvastatin followed by niacin was assessed.
Main Results:
- Fluvastatin-bezafibrate combination significantly increased HDL cholesterol and reduced triglycerides.
- Fluvastatin-cholestyramine combinations showed dose-dependent LDL cholesterol reduction.
- Fluvastatin-niacin combination achieved greater LDL reduction than niacin monotherapy with good tolerability.
Conclusions:
- Combination therapies involving fluvastatin demonstrate significant lipid-modifying effects.
- Fluvastatin combinations with bezafibrate, cholestyramine, and niacin appear safe and well-tolerated.
- These combinations offer potential for optimal management of hypercholesterolemia and mixed dyslipidemia.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...